Bernstein Harold 4

What Happened

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options to acquire 15,000 shares at $10.42 each (cost $156,300) on Feb 2, 2026.
• On the same day he sold a total of 15,000 shares in multiple open-market transactions for aggregate proceeds of approximately $690,333 (sales were executed at several prices; weighted averages reported).
• The filing also reports a 15,000-share derivative disposition at $0.00 on the same date (see Key Details and Footnotes).

Key Details

• Transaction date: February 2, 2026; Form 4 filed Feb 4, 2026 (timely).
• Exercise/acquisition: 15,000 shares at $10.42 each — $156,300 total.
• Open-market sales: four lots totaling 15,000 shares; reported proceeds ≈ $690,333. Reported weighted-average prices correspond to ranges: $44.15–$44.29, $45.20–$46.19, $46.20–$47.17 (see footnotes F2–F4).
• Derivative disposition: 15,000 shares reported at $0.00 (listed as a derivative transaction).
• Shares owned after the transactions: not specified in the provided filing details.
• Notable footnotes: F1 — sales effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025; F5 — vesting schedule for the option award (1/4 on Oct 3, 2023 then monthly 1/48th thereafter). F2–F4 explain weighted-average pricing ranges and offer to provide detailed per-price sale breakdowns on request.

Context

• This filing shows both an option exercise (acquisition) and immediate sales; exercises followed by same-day sales are often used to cover exercise costs or realize gains. The sales were executed under a pre-existing 10b5-1 plan (per F1), indicating pre-scheduled transactions rather than ad hoc trading.
• The derivative line reported at $0.00 and the vesting footnote relate to the option/award mechanics; the filing does not itself explain whether shares were surrendered for taxes or other internal settlement mechanics.